Abstract

At OSUCCC, the stimulus for protocol development comes from the Disease Specific Committees. Priorities for accrual to studies are also set by the Committees. Individuals seek design advice and formatting help from the Interdisciplinary Oncology Unit in the preparation of proposals for submission to both the Scientific Review Committee (SRC) of the Center, and the Institutional Review Board (IRB), which are separate entities. Investigators can choose to send their proposal either the SRC or the IRB first. Investigators may appear to defend their study and outside consultants are appropriate. The SRC monitors the progress of each institutional study for accrual on a regular basis. There are clearly defined stopping rules and the SRC appears to have the authority to implement them. The quality of data is audited by an Audit Committee whose minutes were supplied for review to the site visitors. This committee meets monthly and reviews a random selection of charts for protocol compliance. The Institution is in the process of establishing an office to monitor clinical studies that will have overarching responsibilities to assure quality of data.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-21
Application #
3729047
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
21
Fiscal Year
1995
Total Cost
Indirect Cost

  Institution

Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210

  Publications

Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Pan, Pan; Oshima, Kiyoko; Huang, Yi-Wen et al. (2018) Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer 143:886-896

Showing the most recent 10 out of 2602 publications